Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — administered with or without a glycoprotein 100 (...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hodi, F. Stephen, O’Day, Steven J., McDermott, David F., Weber, Robert W., Sosman, Jeffrey A., Haanen, John B., Gonzalez, Rene, Robert, Caroline, Schadendorf, Dirk, Hassel, Jessica C., Akerley, Wallace, van den Eertwegh, Alfons J.M., Lutzky, Jose, Lorigan, Paul, Vaubel, Julia M., Linette, Gerald P., Hogg, David, Ottensmeier, Christian H., Lebbé, Celeste, Peschel, Christian, Quirt, Ian, Clark, Joseph I., Wolchok, Jedd D., Weber, Jeffrey S., Tian, Jason, Yellin, Michael J., Nichol, Geoffrey M., Hoos, Axel, Urba, Walter J.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549297/
https://ncbi.nlm.nih.gov/pubmed/20525992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1003466
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki